Topline results were announced from a phase 3 trial evaluating the safety, tolerability, and immunogenicity of Pfizer-BioNTech’s LP.8.1-adapted COVID-19 vaccine.

For patients with acute myocardial infarction (MI), beta-blockers are not beneficial in those without reduced left ventricular ejection fraction (LVEF).

Reducing thrombolysis-to-puncture time improves outcomes in patients with AIS caused by LVO receiving IVT followed by EVT.

Semaglutide was associated with a significantly greater reduction in MACE risk vs tirzepatide in patients with overweight/obesity and CVD.

Vonvendi is a recombinant von Willebrand factor previously only approved for on-demand and perioperative use in adults with VWD and routine prophylactic use in adults with severe Type 3 VWD receiving ...

Topline data were announced from a trial evaluating enlicitide in adults with hypercholesterolemia on a moderate or high intensity statin.

Adults with obesity prefer a primary care visit characterized by respectful treatment and listening, according to a study published online.

In patients with in-hospital silent graft occlusion after CABG, there is increased risk for angina-related rehospitalization and revascularization.

The FDA has accepted for review the NDA for ensitrelvir for the prevention of COVID-19 following exposure to an infected individual.

For women with myocardial infarction (MI), beta-blocker therapy is associated with worse outcomes, according to a study published online.

Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient per year.

Oral spironolactone 25 mg daily does not improve CV mortality or hospitalization risk related to HF among patients with kidney failure receiving dialysis.